USPTO Patent Application for Immunoconjugates
Summary
The USPTO has published a new patent application, US20260083855A1, filed by Hoffmann-La Roche Inc. The application relates to immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. This filing is part of the standard patent application process.
What changed
The United States Patent and Trademark Office (USPTO) has published patent application US20260083855A1, filed on July 11, 2025, by Hoffmann-La Roche Inc. The application details novel immunoconjugates, specifically those combining a mutant interleukin-2 polypeptide with an antibody targeting PD-1. It also covers related polynucleotides, vectors, host cells, production methods, pharmaceutical compositions, and their therapeutic uses, particularly in oncology.
This publication represents a new patent filing and does not impose immediate regulatory obligations on companies. However, it signifies ongoing innovation in the biopharmaceutical sector, particularly in cancer therapeutics. Companies operating in this space, especially those developing similar immunotherapies or antibody-drug conjugates, should be aware of this filing as it may impact future intellectual property landscapes and competitive strategies.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
IMMUNOCONJUGATES
Application US20260083855A1 Kind: A1 Mar 26, 2026
Assignee
Hoffmann-La Roche Inc.
Inventors
Laura CODARRI DEAK, Anne FREIMOSER-GRUNDSCHOBER, Ralf Joerg HOSSE, Christian KLEIN, Ekkehard MOESSNER, Valeria GONZALEZ NICOLINI, Pablo UMAÑA FERNÁNDEZ, Inja WALDHAUER
Abstract
The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
CPC Classifications
A61K 47/6813 A61K 47/6849 A61K 47/6889 A61P 35/00 C07K 14/55 C07K 16/2818 A61K 38/00 C07K 2319/00
Filing Date
2025-07-11
Application No.
19267102
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.